Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies

Sonam Puri,Michael Shafique

DOI: https://doi.org/10.7573/dic.2019-9-2

2020-01-13

Drugs in Context

Abstract:This review discusses the rationale, outcomes, and challenges of combination immune checkpoint blockade in non-small-cell lung cancer (NSCLC).